GelCOUNT Bibliography

Selected List of Publications


Hannafon BN, Cai A, Calloway CL, Xu YF, Zhang R, Fung KM and Ding WQ (2019). miR-23b and miR-27b are oncogenic microRNAs in breast cancer: evidence from a CRISPR/Cas9 deletion study. BMC Cancer 19(1), 642


Giordano A, Liu Y, Armeson K, Park Y, Ridinger M, Erlander M, Reuben J, Britten C, Kappler C, Yeh E and Ethier S (2019). Polo-like kinase 1 (Plk1) inhibition synergizes with taxanes in triple negative breast cancer. PLoS One 14(11), e0224420


Hale SJ, Jimenez-Pascual A, Kordowski A, Pugh J, Rao S, Silver DJ, Alban T, Watson DB, Chen R, McIntyre TM, Colombo G, Taraboletti G, Holmberg KO, Forsberg-Nilsson K, Lathia JD and Siebzehnrubl FA (2018). ADAMDEC1 maintains a novel growth factor signaling loop in cancer stem cells. doi:


Sun L et al. (2019).  miR-302a Inhibits Metastasis and Cetuximab Resistance in Colorectal Cancer by Targeting NFIB and CD44. Theranostics 9(26), 8409-8425


Kessel D (2019). Pathways to Paraptosis After ER Photodamage in OVCAR-5 Cells. Photochem Photobiol. 2019 Mar 29. doi: 10.1111/php.13103. [Epub ahead of print]


Wienholz F, Zhou D, Turkyilmaz Y, Schwertman P, Tresini M, Pines A, van Toorn M, Bezstarosti K, Demmers JAA and Marteijn JA (2019). FACT subunit Spt16 controls UVSSA recruitment to lesion-stalled RNA Pol II and stimulates TC-NER. Nucleic Acids Res. 2019 Feb 4. doi: 10.1093/nar/gkz055. [Epub ahead of print]


Ha JR, Ahn R, Smith HW, Sabourin V, H?bert S, Cepeda Cañedo E, Im YK, Kleinman C, Muller WJ and Ursini-Siegel J (2018). Integration of distinct ShcA signaling complexes promotes breast tumor growth and tyrosine kinase inhibitor resistance. Mol Cancer Res 16(5), 894-908


Bao, Y., Oguz, G., Lee, W.C. et al. EZH2-mediated PP2A inactivation confers resistance to HER2-targeted breast cancer therapy. Nat Commun 11, 5878 (2020).




Simon J.A. Buczacki,1 Semiramis Popova,1 Emma Biggs,1 Chrysa Koukorava,1 Jon Buzzelli,3 Louis Vermeulen,2 Lee Hazelwood,1 Hayley Francies,4 Mathew J. Garnett,4 and Douglas J. Winton1

Itraconazole targets cell cycle heterogeneity in colorectal cancer. J Exp Med (2018) 215 (7): 1891–1912. 


Cancer-associated fibroblasts suppress SOX2-induced dysplasia in a lung squamous cancer coculture Shuang Chena,1, Andreas Giannakoua,1, Sarah Wymana , Janet Gruzasa , Jonathon Golasa , Wenyan Zhonga , Christine Loretha , Latha Sridharana , Ting-Ting Yamina , Marc Damelina , and Kenneth G. Gelesa,2



RON signalling promotes therapeutic resistance in ESR1 mutant breast cancer
Derek Dustin1,2, Guowei Gu1,3, Amanda R. Beyer1, Sarah K. Herzog1,4, David G. Edwards1, Hangqing Lin1, Thomas L. Gonzalez1, Sandra L. Grimm3,5, Cristian Coarfa3,5, Doug W. Chan1, Beom-Jun Kim1, Jean-Paul De La O6, Matthew J. Ellis1,2,7, Dan Liu8, Shunqiang Li9, Alana L. Welm 6 and Suzanne A. W. Fuqua

British Journal of Cancer 124 , 191–206



For a complete listing of papers citing the GelCOUNT please visit this link: